Background: Given the ongoing COVID-19 pandemic, it is crucial to prioritize the management of underlying diseases in infected patients, with hypertension being one of the most common conditions. However, there lies a complicated correlation between antihypertensive agents and COVID-19 infection.
Objectives: This study is to systematically evaluate the impact of continuing or discontinuing antihypertensive agents on mortality and infection severity in hospitalized patients with both hypertension and COVID-19.
Methods: A systematic electronic search was conducted on PubMed, Embase, Cochrane, Web of Science, and ClinicalTrials.gov to identify relevant clinical trials published between 1948 and September 2022. Two independent reviewers assessed the quality of the included studies and extracted relevant data. The primary outcome of interest was the relationship between in-hospital mortality and administration of antihypertensive agents.
Results: The meta-analysis revealed that continuous administration of antihypertensive agents, compared with discontinuation, significantly reduced in-hospital mortality among hypertension patients with COVID-19 infection [OR=0.49, 95 %CI (0.38, 0.65), p < 0.001, I=65.3 %]. Specifically, patients receiving ACEI/ARB type agents had even lower mortality rates. Meta-regression analyses were conducted to examine the impact of publication date, sample size, study design, and mean age of the patients, and the results showed that the number of participants in the included studies was the primary source of heterogeneity (p = 0.032). The findings indicated a clear association between the use of antihypertensive agents and reduced mortality in these patients.
Conclusion: nder the current circumstance of the sustained COVID-19 pandemic, it is recommended to continue the use of antihypertensive agents for patients with hypertension during COVID-19 infection, as it can help reduce the risk of mortality.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.hrtlng.2023.10.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical Decision Support and Cardiometabolic Medication Adherence: A Randomized Clinical Trial.
JAMA Netw Open
January 2025
HealthPartners Institute, Bloomington, Minnesota.
Importance: Medication adherence is important for managing blood pressure (BP), low-density lipoprotein cholesterol (LDL-C), and hemoglobin A1c (HbA1c). Interventions to improve medication adherence are needed.
Objective: To examine the effectiveness of an intervention using algorithmic identification of low medication adherence, clinical decision support to physicians, and pharmacist outreach to patients to improve cardiometabolic medication adherence and BP, LDL-C, and HbA1c control.
Biomarkers.
Alzheimers Dement
December 2024
Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Background: In the Systolic Blood Pressure Intervention Trial (SPRINT), intensive systolic blood pressure (SBP) lowering slowed progression of white matter injury (WMI) on MRI. We hypothesized that intensive lowering would be equally as effective and may confer greater benefits for brain health at younger ages compared to older ages. We tested whether the relative effects of intensive lowering on WMI differed by age using 2 MRI measures: white matter hyperintensity volume (WMHv) and peak-width skeletonized mean diffusivity (PSMD) in SPRINT.
View Article and Find Full Text PDFBackground: Alzheimer's Disease (AD) is a complex neurodegenerative disease characterized by multiple etiologies that remains without a cure. Diabetes, dyslipidemia, hypertension, and inflammation are well-known risk factors for AD, and FDA-approved therapeutics for these conditions have been associated with a reduced risk of developing AD. This study aims to evaluate the impact of diabetes medications (DBMD), lipid-lowering (LIPL), antihypertensive (AHTN), and non-steroidal anti-inflammatory (NSD) therapeutics, alone or combined, on cognitive performance in an AD population.
View Article and Find Full Text PDFBackground: Dementia is a growing global public health challenge. Previous meta-analyses have found that systemic medications may modulate dementia risk. We aimed to provide an overview of this evidence.
View Article and Find Full Text PDFPublic Health.
Alzheimers Dement
December 2024
Erasmus University Medical Center, Rotterdam, Zuid-Holland, Netherlands.
Background: Hypertension is an important modifiable risk factor for dementia, but the role of blood pressure (BP) in the development of dementia is not fully understood. Emerging data links increased BP variability and abnormal BP dynamics to dementia risk, but the relationship between baroreflex sensitivity (BRS), a fundamental physiological mechanism for maintaining stable BP, and dementia risk is unknown.
Methods: We investigated the association of BRS with the risk of dementia in community-based older adults from the Rotterdam Study in the Netherlands.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!